| Meropenem | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | |
| Meropenem | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | |
| Meropenem | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | |
| Meropenem | hsa04015 | Rap1 signaling pathway | 2.05E-03 | 4 | P25116, Q8TEU7, P08514, P17252 | F2R, RAPGEF6, ITGA2B, PRKCA | More | |
| Meropenem | hsa04022 | cGMP-PKG signaling pathway | 1.05E-02 | 3 | P24844, Q8WYR1, Q15746 | MYL9, PIK3R5, MYLK | More | |
| Meropenem | hsa04024 | cAMP signaling pathway | 1.40E-02 | 3 | P48058, P25116, P24844 | GRIA4, F2R, MYL9 | More | |
| Meropenem | hsa04270 | Vascular smooth muscle contraction | 4.65E-02 | 2 | Q15746, P24844 | MYLK, MYL9 | More | |
| Meropenem | hsa04510 | Focal adhesion | 3.36E-02 | 3 | P08514, Q15746, P24844 | ITGA2B, MYLK, MYL9 | More | |
| Meropenem | hsa04512 | ECM-receptor interaction | 2.44E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | |
| Meropenem | hsa04514 | Cell adhesion molecules | 4.65E-02 | 2 | P16109, O00501 | SELP, CLDN5 | More | |
| Meropenem | hsa04530 | Tight junction | 7.42E-04 | 4 | Q8TEU7, O00501, Q14247, P24844 | RAPGEF6, CLDN5, CTTN, MYL9 | More | |
| Meropenem | hsa04610 | Complement and coagulation cascades | 2.94E-02 | 2 | P25116, P10909 | F2R, CLU | More | |
| Meropenem | hsa04611 | Platelet activation | 7.40E-06 | 5 | P25116, P08514, Q15746, Q8WYR1, P07359 | F2R, ITGA2B, MYLK, PIK3R5, GP1BA | More | |
| Meropenem | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | |
| Meropenem | hsa04724 | Glutamatergic synapse | 2.94E-02 | 2 | P48058, Q9NSB8 | GRIA4, HOMER2 | More | |
| Meropenem | hsa04810 | Regulation of actin cytoskeleton | 1.38E-03 | 4 | P24844, Q15746, P08514, P25116 | MYL9, MYLK, ITGA2B, F2R | More | |
| Meropenem | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | |
| Meropenem | hsa04921 | Oxytocin signaling pathway | 6.37E-03 | 3 | Q15746, P24844, Q8WYR1 | MYLK, MYL9, PIK3R5 | More | |
| Meropenem | hsa05130 | Pathogenic Escherichia coli infection | 2.51E-02 | 3 | Q14247, O00501, P25116 | CTTN, CLDN5, F2R | More | |
| Meropenem | hsa05205 | Proteoglycans in cancer | 4.46E-02 | 4 | Q12955, Q14247, P17252, P08962 | ANK3, CTTN, PRKCA, CD63 | More | |
| Meropenem | hsa05310 | Asthma | 1.35E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Meropenem | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Meropenem | hsa05330 | Allograft rejection | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Meropenem | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | |
| Meropenem | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
